Lantheus Medical Imaging of North Billerica, MA, has signed a deal to license the CardioGen-82 rubidium-82 PET radiopharmaceutical from Bracco Diagnostics of Princeton, NJ.
CardioGen-82 is the only generator-based PET cardiac perfusion agent approved by the U.S. Food and Drug Administration (FDA) and reimbursed for coronary artery disease evaluation, according to the companies. The radiotracer was approved by the FDA in 1989 and has been used in hundreds of thousands of patients since then, the companies said.
CardioGen sales have been experiencing double-digit year-over-year growth since 2003, and the firms expect that the new deal will further add to the product's sales.
Related Reading
Definity echo contrast agent lands on FDA drug safety list, September 8, 2008
IBA, Lantheus ink radiopharma deal, July 31, 2008
Lantheus reports data from cardiac PET trial, June 17, 2008
Bracco, Novation ink supply deal, September 3, 2008
Bracco touts contrast study results, August 5, 2008
Copyright © 2008 AuntMinnie.com
